Vaccination against shigellosis with attenuated Shigella flexneri 2a strain SC602 - Wikidata - awgldk - TriplyDB

Vaccination against shigellosis with attenuated Shigella flexneri 2a strain SC602

Vaccination against shigellosis with attenuated Shigella flexneri 2a strain SC602

http://www.wikidata.org/entity/Q33876803

about

Immunogenicity and efficacy of oral vaccines in developing countries: lessons from a live cholera vaccine Shigella Diversity and Changing Landscape: Insights for the Twenty-First Century A multicentre study of Shigella diarrhoea in six Asian countries: disease burden, clinical manifestations, and microbiology Immunology of Gut Mucosal Vaccines Immunoproteome analysis of soluble and membrane proteins of Shigella flexneri 2457T.A genome-scale proteomic screen identifies a role for DnaK in chaperoning of polar autotransporters in Shigella.A changing picture of shigellosis in southern Vietnam: shifting species dominance, antimicrobial susceptibility and clinical presentation Virulence, inflammatory potential, and adaptive immunity induced by Shigella flexneri msbB mutants Construction and characterization of bivalent Shigella flexneri 2a vaccine strains SC608(pCFAI) and SC608(pCFAI/LTB) that express antigens from enterotoxigenic Escherichia coli.Attenuated Shigella flexneri 2a vaccine strain CVD 1204 expressing colonization factor antigen I and mutant heat-labile enterotoxin of enterotoxigenic Escherichia coli.Virulence factors associated with pediatric shigellosis in Brazilian Amazon.A piglet model of acute gastroenteritis induced by Shigella dysenteriae Type 1 Polar targeting of Shigella virulence factor IcsA in Enterobacteriacae and Vibrio The immune responses to bacterial antigens encountered in vivo at mucosal surfaces.Outer membrane protein A (OmpA) of Shigella flexneri 2a, induces protective immune response in a mouse model.Shigella flexneri 2a strain CVD 1207, with specific deletions in virG, sen, set, and guaBA, is highly attenuated in humans.Parameters underlying successful protection with live attenuated mutants in experimental shigellosis Safety and immunogenicity of a proteosome-Shigella flexneri 2a lipopolysaccharide vaccine administered intranasally to healthy adults.Predominance of serotype-specific mucosal antibody response in Shigella flexneri-infected humans living in an area of endemicity.Phase I evaluation of delta virG Shigella sonnei live, attenuated, oral vaccine strain WRSS1 in healthy adults Community-based safety, immunogenicity, and transmissibility study of the Shigella sonnei WRSS1 vaccine in Israeli volunteers Shigella isolates from the global enteric multicenter study inform vaccine development.Characterization of WRSs2 and WRSs3, new second-generation virG(icsA)-based Shigella sonnei vaccine candidates with the potential for reduced reactogenicity.Live attenuated S. Typhimurium vaccine with improved safety in immuno-compromised mice.Differential response of the cynomolgus macaque gut microbiota to Shigella infection Bacterial infectious disease control by vaccine development.Targeting cancer's weaknesses (not its strengths): Therapeutic strategies suggested by the atavistic model Shigella flexneri 3a outer membrane protein C epitope is recognized by human umbilical cord sera and associated with protective activity Analysis of virulence and inflammatory potential of Shigella flexneri purine biosynthesis mutants Prevention and self-treatment of traveler's diarrhea.Shigella outer membrane protein PSSP-1 is broadly protective against Shigella infection.Vaccines for viral and bacterial pathogens causing acute gastroenteritis: Part II: Vaccines for Shigella, Salmonella, enterotoxigenic E. coli (ETEC) enterohemorragic E. coli (EHEC) and Campylobacter jejuni.Enteric pathogens as vaccine vectors for foreign antigen delivery Evaluation of the Safety, Tolerability, and Immunogenicity of an Oral, Inactivated Whole-Cell Shigella flexneri 2a Vaccine in Healthy Adult Subjects.Clinical trials of Shigella vaccines: two steps forward and one step back on a long, hard road.Type III secretion systems and disease.Establishment of a Shigella sonnei human challenge model in Thailand.Progress and pitfalls in Shigella vaccine research.Changing trends and serotype distribution of Shigella species in Beijing from 1994 to 2010 Finding Potential Therapeutic Targets against Shigella flexneri through Proteome Exploration

P2860

Q21245322-5DEB5586-C92C-4306-AAA7-3792D1B1EDD9 Q26752367-3329EC5D-54D1-4632-934F-CB00F9169A47 Q28767862-492BB4EA-7665-47CA-AC9A-D78BEBE9C78B Q28972559-FE682855-995B-4E2A-9132-E72D388E87E2 Q33262196-43DCB573-210E-48A8-8177-EE4040F978D7 Q33493807-B2A5E9FC-9D9E-4102-8E53-2858AAE4349F Q33518017-98D8EA93-11C9-4671-BA2E-8471A04C0179 Q33557800-324E8791-3633-4E40-8385-04389D1D30CA Q33558374-CFF228A0-4F8C-466E-AF83-593F90EA33FA Q33597022-96114964-74F8-4FE9-B72B-C6D91D9DCFD1 Q33608925-72F3A6F3-DD95-4D9E-AE8D-1C78E9C2E9BD Q33678906-BC8B99DC-A554-4207-B12A-2488F82F1AF7 Q33934139-F0F33E6A-7260-412C-9F14-207CD484A702 Q33955531-12AC2A4D-DF20-4366-BFA5-6234F2031E32 Q33983350-D3F48233-15CE-4E4F-AD37-C08015A89CC4 Q34003433-3569BCAF-7FE4-4A46-ACEB-D1E57512B5AE Q34006071-7314C482-BB04-4170-B574-D1019B217753 Q34008338-4F149F42-1097-488A-AFCD-74ADA62E44BC Q34008763-5D1BE0EE-409A-437F-8C76-0BB70A168C2F Q34120926-321B7323-0732-4A33-AB1E-2F5C159FE8F9 Q34194587-FE4F4844-44EB-4352-90C3-ECB3B6DE7DA4 Q34202171-FA062FBA-37B5-485E-A7A3-423519BC0151 Q34394744-D1CC34F0-502F-4601-905E-B150D52ED1A0 Q34429033-01E86ED0-3291-4C6C-9FB8-D2D4D7FCB026 Q34765669-D45A07ED-0607-4E86-9A88-A099FC470D61 Q34785982-A602EB20-5063-41B5-9417-36B5FB3D5C89 Q34807615-56D94621-C501-4D92-8AFD-1C9E691C85B2 Q34935297-899544EA-D631-43AB-8D98-8EF8E7F242CC Q34941041-CD6FC8DE-AD13-4401-B501-E4C57043C7D3 Q34974972-42F6FF6C-DE0D-40F1-B014-12499408E452 Q35221181-B555E926-7F15-4627-936E-37F418F50D65 Q35887055-6393821B-E211-4768-95F2-9FE71198D7F4 Q35896020-740E0CA6-D46A-47F4-8307-88D604289FFA Q36764372-58900109-4C15-4536-8842-40AD749045DF Q36844719-B59C768B-AA42-4008-A82A-A2E5D0E7E9AE Q36969851-0F29C6CA-5298-4149-9080-7F40C048BC5C Q37066116-8A910213-8CCC-46C8-91B6-141390DA11CE Q37105553-6CD1CE14-EF31-4BE0-8EEF-350F355D0250 Q37113756-3424E79B-0E8D-437F-B5B9-6B0B835BAE0D Q37427534-EF317BB8-0B00-4779-A5F1-163F96C251C8

P2860

Vaccination against shigellosis with attenuated Shigella flexneri 2a strain SC602

http://www.wikidata.org/entity/Q33876803

description

1999 nî lūn-bûn

@nan

1999 թուականի Յուլիսին հրատարակուած գիտական յօդուած

@hyw

1999 թվականի հուլիսին հրատարակված գիտական հոդված

@hy

1999年の論文

@ja

1999年論文

@yue

1999年論文

@zh-hant

1999年論文

@zh-hk

1999年論文

@zh-mo

1999年論文

@zh-tw

1999年论文

@wuu

name

Vaccination against shigellosis with attenuated Shigella flexneri 2a strain SC602

@ast

Vaccination against shigellosis with attenuated Shigella flexneri 2a strain SC602

@en

type

label

Vaccination against shigellosis with attenuated Shigella flexneri 2a strain SC602

@ast

Vaccination against shigellosis with attenuated Shigella flexneri 2a strain SC602

@en

prefLabel

Vaccination against shigellosis with attenuated Shigella flexneri 2a strain SC602

@ast

Vaccination against shigellosis with attenuated Shigella flexneri 2a strain SC602

@en

P1433

Q33876803-CDB6F4B8-C430-4791-9F07-6CD9C8865129

P1476

Q33876803-39C4CDD9-10A2-4481-A295-2441461E09C7

P2093

Q33876803-207D90E1-726F-4142-8F9D-E0B74E0D7D55

Q33876803-235A7070-F89A-4B69-8785-4100D5419E68

Q33876803-4B65230B-C16F-46C5-8C4F-7A869A8CECD2

Q33876803-4DBE80E9-BCCD-4926-8EDF-6A04617860A3

Q33876803-6231278F-2F89-4925-8202-354F0E44EC0A

Q33876803-68EA8CF9-48A9-4BE5-8C58-6065064B3959

Q33876803-842D85CC-16E6-4789-88A4-B3382E47DCCF

Q33876803-A4A5482F-1322-471D-AF4E-B6F96512AC6E

Q33876803-A8F7FA41-D760-4C3A-87A6-3B4B87F6D18C

Q33876803-E0C5FDAD-B07B-4EEF-BAC2-277EE18BE990

P2860

Q33876803-00138A16-B637-4DF5-A807-C446CA2B0BD1

Q33876803-01F5A2C5-0887-45E8-8571-868FA3D7C686

Q33876803-03E4FF37-2DB3-47DE-B7CD-DCD16EEEC540

Q33876803-085B2661-5C39-47FF-B450-650761D81F86

Q33876803-0B020862-9EEE-4D4C-A5BA-1CFB503B6017

Q33876803-2191C3C7-0A20-4B45-B6E6-8C23AE5371B0

Q33876803-28A99E21-88F7-4B28-8D6F-1C470E7784BF

Q33876803-31BE3F19-98DA-4A75-8295-866CD491C85F

Q33876803-3ADB318F-3E2A-4590-98E2-87C7A1038CFE

Q33876803-3FAC5594-E6DA-4132-9A60-3DA69B2B5F6F

P304

Q33876803-0A24AEA2-CDA3-49F3-B8D5-2B1DB8A4D1E5

P31

Q33876803-F6FD5D38-11B0-49EC-A77B-D083D6171212

P407

Q33876803-555D2562-C1B2-4C08-96F0-7F1FA2F49838

P433

Q33876803-9434685B-1792-4DA3-849F-ECF7FE1B44B5

P478

Q33876803-5A1F996B-6DB4-4380-A267-331BE989E4C7

P577

Q33876803-4DDAEA7E-F380-4893-876E-9C27E3D2BF6F

P698

Q33876803-A7D74AEC-B148-4C16-8356-E725D033CD7E

P921

Q33876803-31715AF9-235E-4C75-B954-0797B12EA7D8

Q33876803-5AB7AC5C-05B7-4B43-AA28-5EFFE1555B76

P932

Q33876803-14810773-4266-4827-A0ED-0858931F75DB

P1433

Infection and Immunity

P1476

Vaccination against shigellosis with attenuated Shigella flexneri 2a strain SC602

@en

P2093

A B Hartman

http://www.w3.org/2001/XMLSchema#string

A Fontaine-Thompson

http://www.w3.org/2001/XMLSchema#string

C W Hoge

http://www.w3.org/2001/XMLSchema#string

D Cohen

http://www.w3.org/2001/XMLSchema#string

E V Oaks

http://www.w3.org/2001/XMLSchema#string

G Robin

http://www.w3.org/2001/XMLSchema#string

L L VanDeVerg

http://www.w3.org/2001/XMLSchema#string

M M Venkatesan

http://www.w3.org/2001/XMLSchema#string

P J Sansonetti

http://www.w3.org/2001/XMLSchema#string

T L Hale

http://www.w3.org/2001/XMLSchema#string

P2860

Identification of icsA, a plasmid locus of Shigella flexneri that governs bacterial intra- and intercellular spread through interaction with F-actin.

Construction and characterization of attenuated delta aroA delta virG Shigella flexneri 2a strain CVD 1203, a prototype live oral vaccine

Detection of antibodies to Shigella lipopolysaccharide in urine after natural Shigella infection or vaccination.

Induction of a local anti-IpaC antibody response in mice by use of a Shigella flexneri 2a vaccine candidate: implications for use of IpaC as a protein carrier.

Safety, immunogenicity, and transmissibility in humans of CVD 1203, a live oral Shigella flexneri 2a vaccine candidate attenuated by deletions in aroA and virG.

Acute inflammation causes epithelial invasion and mucosal destruction in experimental shigellosis

Safety, immunogenicity, and efficacy in monkeys and humans of invasive Escherichia coli K-12 hybrid vaccine candidates expressing Shigella flexneri 2a somatic antigen.

Movement along actin filaments of the perijunctional area and de novo polymerization of cellular actin are required for Shigella flexneri colonization of epithelial Caco-2 cell monolayers

Specific immunoglobulin A-secreting cells in peripheral blood of humans following oral immunization with a bivalent Salmonella typhi-Shigella sonnei vaccine or infection by pathogenic S. sonnei

Small-animal model to measure efficacy and immunogenicity of Shigella vaccine strains.

P304

3437-3443

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P407

P433

7

http://www.w3.org/2001/XMLSchema#string

P478

67

http://www.w3.org/2001/XMLSchema#string

P577

1999-07-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

10377124

http://www.w3.org/2001/XMLSchema#string

P921

Shigella flexneri

attenuated vaccine

P932

116529

http://www.w3.org/2001/XMLSchema#string